Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Elicio Therapeutics (ELTX) Shares Outstanding (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Shares Outstanding readings, the most recent being $9.6 million for Q4 2023.

  • On a quarterly basis, Shares Outstanding rose 2903.04% to $9.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was $9.6 million, a 2903.04% increase, with the full-year FY2023 number at $9.6 million, up 2903.04% from a year prior.
  • Shares Outstanding hit $9.6 million in Q4 2023 for Elicio Therapeutics, up from $8.4 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $30.4 million in Q3 2021 to a low of -$312164.0 in Q1 2020.
  • Median Shares Outstanding over the past 4 years was $8.4 million (2023), compared with a mean of $10.3 million.
  • Biggest five-year swings in Shares Outstanding: surged 9842.97% in 2021 and later plummeted 98.96% in 2022.
  • Elicio Therapeutics' Shares Outstanding stood at $15.6 million in 2020, then crashed by 98.02% to $310200.0 in 2021, then rose by 3.25% to $320281.0 in 2022, then surged by 2903.04% to $9.6 million in 2023.
  • The last three reported values for Shares Outstanding were $9.6 million (Q4 2023), $8.4 million (Q3 2023), and $8.4 million (Q2 2023) per Business Quant data.